CytomX Therapeutics
Financial ratios & Valuation

Forward Multiples (2025 – 2028)

2025202620272028
Price/Earnings ratio
-4.23-2.45-2.01-3.88
Price/Sales ratio
1.713.005.221.36
Earnings per Share (EPS)
$-0.47$-0.81$-0.99$-0.51

Historical Multiples (2014 – 2023)

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 TTM Median
Valuation Ratios
Price/Earnings ratio
-14.86-5.07-6.76-18.20-7.43-3.68-9.19-3.44-1.08-201.05-0.74-7.43
Price/Sales ratio
88.7323.2626.4710.9510.576.553.013.991.971.131.246.55
Price/Book Value ratio
-5.731.425.0711.224.807.376.063.10-1.22-2.41-1.287.37
Price/Cash Flow ratio
14.16-6.54-195.974.60-8.33-2.6857.47-2.33-0.94-2.04-0.59-8.33
Price/Free Cash Flow ratio
14.94-6.18-94.634.64-7.93-2.61102.45-2.30-0.93-2.01-0.58-7.93
Price/Earnings Growth ratio
-0.14-0.010.110.63-0.09-0.320.13-0.04-0.062.020.06-0.09
Dividend Yield
N/A3.73%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Profitability Indicator Ratios
Gross Profit Margin
100%100%100%100%100%100%100%91.60%88.98%100%20.53%100%
Operating Profit Margin
-586.27%-430.53%-396.10%-64.58%-130.87%-192.89%-48.42%-120.42%-190.61%-6.40%-169.60%-192.89%
Pretax Profit Margin
-596.80%-458.55%-391.67%-60.89%-118.14%-178.58%-46.62%-120.17%-186.81%3.28%-166.60%-178.58%
Net Profit Margin
-597.00%-458.68%-391.54%-60.17%-142.18%-177.83%-32.76%-115.91%-183.02%-0.56%-166.60%-177.83%
Effective Tax Rate
-0.03%-0.02%0.03%1.17%-20.34%0.41%29.72%3.54%2.03%117.12%N/A-20.34%
Return on Assets
-41.48%-17.93%-29.57%-10.83%-18.50%-29.95%-9.16%-23.76%-37.29%-0.28%-56.49%-29.95%
Return On Equity
38.59%-28.05%-75.05%-61.66%-64.64%-200.02%-66.03%-90.23%113.46%1.19%-988.75%-200.02%
Return on Capital Employed
-48.08%-18.29%-36.47%-13.74%-21.67%-43.37%-18.85%-35.94%-93.58%-14.13%-138.56%-43.37%
Liquidity Ratios
Current Ratio
N/A12.055.266.354.543.543.21N/AN/AN/A1.553.54
Quick Ratio
5.9712.055.266.354.543.543.212.911.551.171.503.54
Cash ratio
5.763.802.922.902.522.201.901.931.260.111.262.20
Days of Sales Outstanding
134.7935.2156.1251.660.590.082.904.14247.0612.37148.470.59
Days of Inventory outstanding
N/AN/AN/AN/AN/AN/AN/A0.00N/AN/AN/AN/A
Operating Cycle
N/AN/AN/AN/AN/AN/AN/A4.14247.06N/AN/AN/A
Days of Payables Outstanding
N/AN/AN/AN/AN/AN/AN/A176.15175.08N/AN/AN/A
Cash Conversion Cycle
N/AN/AN/AN/AN/AN/AN/A-172.0171.98N/AN/AN/A
Debt Ratios
Debt Ratio
0.04N/AN/AN/AN/A0.070.060.050.050.021.321.32
Debt Equity Ratio
-0.03N/AN/AN/AN/A0.480.430.20-0.16-0.09-4.040.48
Long-term Debt to Capitalization
-0.02N/AN/AN/AN/A0.320.300.16-0.19N/A-0.190.32
Total Debt to Capitalization
-0.03N/AN/AN/AN/A0.320.300.16-0.19-0.10N/A0.32
Interest Coverage Ratio
N/A-19.17-35.27N/AN/AN/AN/AN/AN/AN/A-158.60N/A
Cash Flow to Debt Ratio
10.64N/AN/AN/AN/A-5.640.24-6.59-7.92-12.21N/AN/A
Company Equity Multiplier
-0.931.562.535.683.496.677.203.79-3.04-4.25-3.046.67
Cash Flow Ratios
Operating Cash Flow / Sales Ratio
6.26-3.55-0.132.37-1.26-2.440.05-1.71-2.08-0.55-2.10-2.44
Free Cash Flow / Operating Cash Flow Ratio
0.941.052.070.991.051.020.561.011.011.011.011.02
Cash Flow Coverage Ratio
10.64N/AN/AN/AN/A-5.640.24-6.59-7.92-12.21N/AN/A
Short Term Coverage Ratio
22.41N/AN/AN/AN/AN/AN/AN/AN/A-12.21N/AN/A
Dividend Payout Ratio
N/A-18.95%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A